环孢素A与糖尿病的研究进展

doi:10.3969/j.issn.1000-8535.2017.05.028

广州医药 ›› 2017, Vol. 48 ›› Issue (5): 111-114.DOI: 10.3969/j.issn.1000-8535.2017.05.028

环孢素A与糖尿病的研究进展

韦晓¹, 朱丹², 汪奇峰¹, 刘超¹

1 南京中医药大学附属中西医结合医院,江苏省中医药研究院(南京 210028)
2 江都市人民医院(扬州 225200)

收稿日期:2017-04-27 发布日期:2021-12-01
通讯作者: 刘超,E-mail:liuchao@nfmcn.com
基金资助:
国家自然科学基金(81270861)

Research on the relationship between cyclosporin A and diabetes

WEI Xiao¹, ZHU Dan², WANG Qifeng¹, LIU Chao¹

1 Affiliated Hospital of Integrated Traditional Chinese and Western Medicine, Nanjing University of Chinese Medicine; Jiangsu Province Academy of Traditional Chinese Medicine, Nanjing 210028, China
2 Jiangdu People's Hospital, Yangzhou 225200, China

Received:2017-04-27 Published:2021-12-01

摘要/Abstract

摘要： 环孢素A(cyclosporin A,环孢素A)是强效的免疫抑制剂,常用于抑制器官移植后的排斥反应,器官移植后新发糖尿病与免疫抑制剂的使用有关。除器官移植,环孢素A还被用于治疗其他自身免疫性疾病,例如1型糖尿病。但环孢素A对胰岛β细胞和其他多种器官有毒副作用,长期使用环孢素A会导致胰岛素抵抗和胰岛β细胞功能损伤,这也是器官移植后糖尿病(post-transplant dibetes mellitus,PTDM)的主要原因。因此在糖尿病领域环孢素A的使用需要对病情进行具体分析和仔细斟酌。

关键词: 环孢素A, 免疫抑制剂, 糖尿病, 胰岛素

Abstract: Cyclosporin A (CsA) is a powerful immunosuppressant that is widely used to prevent organ rejection and to treat several autoimmune diseases, such as type 1 diabetes mellitus. Post-transplant diabetes mellitus (PTDM) is related with immunosuppressant. Moreover, there are many toxicity and side effects of CsA on pancreatic β cell and other organs, Long-term treatment of CsA may cause insulin resistance and β cell dyfunction. That's the main reason for post-transplant dibetes mellitus (PTDM). In diabetes mellitus fields, CsA must be used carefully considered.

Key words: Cyclosporin A, Immunosuppressor, Diabetes, Insulin

韦晓, 朱丹, 汪奇峰, 刘超. 环孢素A与糖尿病的研究进展[J]. 广州医药, 2017, 48(5): 111-114.

WEI Xiao, ZHU Dan, WANG Qifeng, LIU Chao. Research on the relationship between cyclosporin A and diabetes[J]. Guangzhou Medical Journal, 2017, 48(5): 111-114.

参考文献

[1] MIYATA H, SATOUH Y, MASHIKO D, et al. Sperm calcineurin inhibition prevents mouse fertility with implications for male contraceptive[J]. Science,2015,350(6259): 442-445.
[2] DAVIDSON J A, WILKINSON A. New-onset diabetes after transplantation 2003 international consensus guidelines: an endocrinologist's view[J]. Diabetes Care, 2004,27(3):805-812.
[3] CHAKKERA H A, WEIL E J, CASTRO J, et al. Hyperglycemia during the immediate period after kidney transplantation[J]. Clin J Am Soc Nephrol, 2009, 4(4):853-859.
[4] HECKING M, HAIDINGER M, DÖLLER D, et al. Early basal insulin therapy decreases new-onset diabetes after renal transplantation[J]. J Am Soc Nephrol, 2012, 23(4):739-749.
[5] CAILLARD S, EPRINCHARD L, PERRIN P, et al. Incidence and risk factors of glucose metabolism disorders in kidney transplant recipients: role of systematic screening by oral glucose tolerance test[J]. Transplantation,2011, 91(7):757-764.
[6] LI H, RAO A, HOGAN P G. Interaction of calcineurin with substrates and targeting proteins[J]. Trends Cell Biol, 2011, 21(2):91-103.
[7] TIAN Y F, TSAI C S, LEE P C, et al. New-onset diabetes mellitus in cyclosporine-treated organ transplant patients in Taiwan: interim analysis (6 months) of postmarketing surveillance[J]. Transplant Proc,2012,44(3): 661-666.
[8] OETJEN E, BAUN D, BEIMESCHE S, et al. Inhibition of human insulin gene transcription by the immunosuppressive drugs cyclosporin A and tacrolimus in primary, mature islets of transgenic mice[J]. Mol Pharmacol,2003, 63(6): 1289-1295.
[9] ØZBAY L A, SMIDT K, MORTENSEN D M, et al. Cyclosporin and tacrolimus impair insulin secretion and transcriptional regulation in INS-1E beta-cells[J]. Br J Pharmacol, 2011, 162(1): 136-146.
[10] RYDÉN A K, WESLEY J D, COPPIETERS K T, et al. Non-antigenic and antigenic interventions in type 1 diabetes[J]. Hum Vaccin Immunother, 2014, 10(4): 838-846.
[11] JENNER M, BRADISH G, STILLER C, et al. Cyclosporin a treatment of young children with newly-diagnosed type 1 (insulin-dependent) diabetes mellitus[J]. Diabetologia,199,35(9): 884-888.
[12] STILLER C R, DUPRE J, GENT M, et al. Effects of cyclosporine in recent-onset juvenile type 1 diabetes: impact of age and duration of disease[J]. J Pediatr,1987, 111(6 Pt 2): 1069-1072.
[13] CHAKKERA H A, KUDVA Y, KAPLAN B. Calcineurin inhibitors: pharmacologic mechanisms impacting both insulin resistance and insulin secretion leading to glucose dysregulation and diabetes mellitus[J]. Clin Pharmacol Ther,2017, 101(1): 114-120.
[14] SAHAY M, SAHAY R K, NARAYAN G, et al. The effects of cyclosporin A and heteropterys tomentosa on the rat liver[J]. Saudi J Kidney Dis Transpl, 2013,24(5): 897-902.
[15] PEREIRA M J, PALMING J, RIZELL M, et al. Cyclosporine A and tacrolimus reduce the amount of GLUT4 at the cell surface in human adipocytes: increased endocytosis as a potential mechanism for the diabetogenic effects of immunosuppressive agents[J]. J Clin Endocrinol Metab, 2014, 99(10): E1885-1894.
[16] MANNERING S I, HARRISON L C, WILLIAMSON N A, et al. The insulin A-chain epitope recognized by human T cells is posttranslationally modified[J]. J Exp Med,2005, 202(9): 1191-1197.
[17] BORLAK J, NIEHOF M. HNF4alpha and HNF1alpha dysfunction as a molecular rational for cyclosporine induced posttransplantation diabetes mellitus[J]. PLoS One, 2009, 4(3): e4662.
[18] SERENO J, VALA H, NUNES S, et al. Cyclosporine A-induced nephrotoxicity is ameliorated by dose reduction and conversion to sirolimus in the rat[J]. J Physiol Pharmacol,2015,66(2): 285-299.
[19] ARNOLD R, PUSSELL B A, PIANTA T J, et al. Association between calcineurin inhibitor treatment and peripheral nerve dysfunction in renal transplant recipients[J]. Am J Transplant, 2013, 13(9): 2426-2432.
[20] de FREITAS K M, ALMEIDA J M, MONTEIRO J C, et al. The effects of cyclosporin A and heteropterys tomentosa on the rat liver[J]. An Acad Bras Cienc,2015, 87(1): 369-379.

环孢素A与糖尿病的研究进展

Research on the relationship between cyclosporin A and diabetes

PDF

可视化

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 15

编辑推荐

Metrics

本文评价

[1]	许思慧, 甄曼华, 龙小云. 妊娠期糖尿病孕妇应用胰岛素治疗对妊娠结局的影响及安全性分析[J]. 广州医药, 2021, 52(6): 39-42.
[2]	麦高阳, 李鲁强. 绝经前后女性2型糖尿病患者C肽水平与代谢综合征的关系[J]. 广州医药, 2021, 52(6): 76-79.
[3]	许怡文, 李清初. 糖尿病肾病患者肾功能恶化进展的危险因素[J]. 广州医药, 2021, 52(5): 40-43.
[4]	骆超锋, 梁叠锋, 关国宏. 瑞格列奈联合胰岛素治疗2型糖尿病临床疗效及对患者血糖水平的影响[J]. 广州医药, 2021, 52(4): 65-67.
[5]	王曦龄, 李军, 李思源, 高群, 王双. 新疆绝经后女性2型糖尿病LRP5基因rs3736228、rs3781586位点的基因多态性及突变与糖、脂、骨代谢关系的研究[J]. 广州医药, 2021, 52(1): 6-11.
[6]	孟艳辉, 高飞, 吴瑞珊, 宋小燕, 彭红波. 血清25(OH)D₃水平对妊娠期糖尿病的预测价值[J]. 广州医药, 2021, 52(1): 39-42.
[7]	张浩航, 曾建红, 平丽, 李佩兰. 2型糖尿病男性患者血尿酸水平与骨质疏松及临床骨折的相关性研究[J]. 广州医药, 2020, 51(5): 46-49.
[8]	谭静. 基于互联网平台的健康管理模式对2型糖尿病患者血糖管理的效果[J]. 广州医药, 2020, 51(5): 111-114.
[9]	陈劲松, 梁绮华. 妊娠期糖尿病与母婴分娩结局的相关性研究[J]. 广州医药, 2020, 51(2): 110-116.
[10]	何伟强. 增生期糖尿病视网膜病变经全视网膜激光治疗的临床观察[J]. 广州医药, 2020, 51(1): 55-58.
[11]	朱敏, 阳灿. 基于微信平台对糖尿病患者的健康管理[J]. 广州医药, 2020, 51(1): 92-95.
[12]	黄绍鹏, 黎志锋, 黎玉送. 以家庭为中心的患教模式与传统综合患教模式对糖尿病患者疗效影响的对比分析[J]. 广州医药, 2020, 51(1): 96-99.
[13]	张燕华, 唐奇志, 陈聪, 刘剑文. 利拉鲁肽与二甲双胍对新诊断2型糖尿病患者骨代谢的影响[J]. 广州医药, 2018, 49(5): 48-51.
[14]	刘思容, 荣新洲, 李庆辉. 糖尿病足患者创面病原菌分布及耐药性变迁[J]. 广州医药, 2018, 49(5): 81-85.
[15]	周扬, 陈菲, 马锋, 黄榕. 汉族、维吾尔族老年男性2型糖尿病合并骨质疏松患者25羟维生素D水平分析[J]. 广州医药, 2018, 49(4): 17-19.